Posted by Michael Wonder on 17 Dec 2025
Wegovy (semaglutide injection) receives conditional marketing authorisation from Health Canada as the first and only treatment for adults with non-cirrhotic MASH, a serious liver disease
15 December 2025 - Novo Nordisk announced today that Health Canada has issued marketing authorisation with conditions (Notice of Compliance with Conditions) for Wegovy (semaglutide injection) for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Authorization in Canada under the NOC/c guidance was granted based on the acceptable safety profile, high quality and promising efficacy of Wegovy (semaglutide injection) observed in Part 1 of the Phase 3 ESSENCE trial.
